Sun Elaine D
Insider CIK 1805339 · DVAX Director · HALO SVP, Chief Financial Officer · RXRX Director
Trades across companies
| Ticker | Code | Trade | Filed | Shares | Price | Value | Owned after | |
|---|---|---|---|---|---|---|---|---|
| RXRX RECURSION PHARMACEUTICALS, | A Award | 2026-06-17 | 2026-06-22 | 88,424 | — | $0 | 135,981 | SEC↗ |
| DVAX DYNAVAX TECHNOLOGIES CORP | D To issuer deriv | 2026-02-10 | 2026-02-10 | 45,000 | — | $0 | 0 | SEC↗ |
| DVAX DYNAVAX TECHNOLOGIES CORP | D To issuer deriv | 2026-02-10 | 2026-02-10 | 11,250 | — | $0 | 0 | SEC↗ |
| DVAX DYNAVAX TECHNOLOGIES CORP | D To issuer deriv | 2026-02-10 | 2026-02-10 | 22,500 | — | $0 | 0 | SEC↗ |
| DVAX DYNAVAX TECHNOLOGIES CORP | D To issuer deriv | 2026-02-10 | 2026-02-10 | 28,500 | — | $0 | 0 | SEC↗ |
| DVAX DYNAVAX TECHNOLOGIES CORP | D To issuer deriv | 2026-02-10 | 2026-02-10 | 22,500 | — | $0 | 0 | SEC↗ |
| DVAX DYNAVAX TECHNOLOGIES CORP | D To issuer | 2026-02-10 | 2026-02-10 | 29,865 | — | $0 | 0 | SEC↗ |
| RXRX RECURSION PHARMACEUTICALS, | A Award deriv | 2025-06-18 | 2025-06-23 | 22,016 | — | $0 | 22,016 | SEC↗ |
| RXRX RECURSION PHARMACEUTICALS, | A Award | 2025-06-18 | 2025-06-23 | 11,008 | — | $0 | 47,557 | SEC↗ |
| DVAX DYNAVAX TECHNOLOGIES CORP | A Award deriv | 2025-06-11 | 2025-06-13 | 28,500 | — | $0 | 28,500 | SEC↗ |
| DVAX DYNAVAX TECHNOLOGIES CORP | A Award | 2025-06-11 | 2025-06-13 | 5,758 | — | $0 | 29,865 | SEC↗ |
| RXRX RECURSION PHARMACEUTICALS, | A Award deriv | 2025-03-17 | 2025-03-19 | 73,099 | — | $0 | 73,099 | SEC↗ |
| RXRX RECURSION PHARMACEUTICALS, | A Award | 2025-03-17 | 2025-03-19 | 36,549 | — | $0 | 36,549 | SEC↗ |
| DVAX DYNAVAX TECHNOLOGIES CORP | A Award deriv | 2024-05-23 | 2024-05-28 | 22,500 | — | $0 | 22,500 | SEC↗ |
| DVAX DYNAVAX TECHNOLOGIES CORP | A Award | 2024-05-23 | 2024-05-28 | 5,357 | — | $0 | 24,107 | SEC↗ |
| DVAX DYNAVAX TECHNOLOGIES CORP | A Award deriv | 2023-05-26 | 2023-05-31 | 22,500 | — | $0 | 22,500 | SEC↗ |
| DVAX DYNAVAX TECHNOLOGIES CORP | A Award | 2023-05-26 | 2023-05-31 | 5,357 | — | $0 | 18,750 | SEC↗ |
| DVAX DYNAVAX TECHNOLOGIES CORP | A Award deriv | 2022-05-26 | 2022-05-27 | 11,250 | — | $0 | 11,250 | SEC↗ |
| DVAX DYNAVAX TECHNOLOGIES CORP | A Award deriv | 2022-05-26 | 2022-05-27 | 2,679 | — | $0 | 2,679 | SEC↗ |
| DVAX DYNAVAX TECHNOLOGIES CORP | A Award deriv | 2021-12-10 | 2021-12-14 | 10,714 | — | $0 | 10,714 | SEC↗ |
| DVAX DYNAVAX TECHNOLOGIES CORP | A Award deriv | 2021-12-10 | 2021-12-14 | 45,000 | — | $0 | 45,000 | SEC↗ |
| HALO HALOZYME THERAPEUTICS, INC | M Exercise deriv | 2021-04-01 | 2021-04-01 | 10,196 | — | $0 | 30,600 | SEC↗ |
| HALO HALOZYME THERAPEUTICS, INC | F Tax w/h | 2021-04-01 | 2021-04-01 | 4,059 | $42.43 | $172.2K | 14,018 | SEC↗ |
| HALO HALOZYME THERAPEUTICS, INC | M Exercise | 2021-04-01 | 2021-04-01 | 10,196 | — | $0 | 18,077 | SEC↗ |
| HALO HALOZYME THERAPEUTICS, INC | M Exercise deriv | 2021-03-02 | 2021-03-02 | 12,166 | — | $0 | 36,496 | SEC↗ |
| HALO HALOZYME THERAPEUTICS, INC | M Exercise | 2021-03-02 | 2021-03-02 | 12,166 | — | $0 | 12,166 | SEC↗ |
| HALO HALOZYME THERAPEUTICS, INC | F Tax w/h | 2021-03-02 | 2021-03-02 | 4,285 | $45.01 | $192.9K | 7,881 | SEC↗ |
| HALO HALOZYME THERAPEUTICS, INC | A Award deriv | 2021-02-15 | 2021-02-17 | 14,898 | — | $0 | 14,898 | SEC↗ |
| HALO HALOZYME THERAPEUTICS, INC | A Award deriv | 2021-02-15 | 2021-02-17 | 25,642 | — | $0 | 25,642 | SEC↗ |
| HALO HALOZYME THERAPEUTICS, INC | A Award deriv | 2020-04-01 | 2020-04-03 | 40,796 | — | $0 | 40,796 | SEC↗ |
| HALO HALOZYME THERAPEUTICS, INC | A Award deriv | 2020-03-02 | 2020-03-04 | 48,662 | — | $0 | 48,662 | SEC↗ |
| HALO HALOZYME THERAPEUTICS, INC | A Award deriv | 2020-03-02 | 2020-03-04 | 104,969 | — | $0 | 104,969 | SEC↗ |